Fragile X syndrome, or "Martin Bell Syndrome", is a hereditary disorder that causes symptoms similar to the autism spectrum and in many cases also causes mental disorders of development.
Fragile X syndrome is the most common inherited cause of autism and mental retardation. To date, despite the efforts of pharmaceutical companies, there is still no approved drug for treatment. A new study suggests that cannabidiol (CBD) treatment may be effective for people with the syndrome.
Fragile X syndrome (SXF) is a dominant X-linked disorder caused by a mutation in the mental retardation of fragile X. Cannabidiol (CBD) is an exogenous phytocannabinoid with therapeutic potential for sufferers anxiety, disorders sleep and deficits cognitiveas well as for populations with endocannabinoid deficiencies, such as those who suffer from SXF (a genetic disorder caused by an X chromosome mutation). The objective of this study was to provide a brief narrative review of the recent literature on endocannabinoids and SXF and to present a series of cases describing three patients with SXF who were treated orally.
This study reveals the importance of exploring the therapeutic potential of CBD in the context of rigorous clinical trials.
Patients participating in the study received oral solutions of oral CBD from 32 to 63,9 mg. In two of the patients, the symptoms worsened after stopping CBD and improved further after treatment was resumed.
The three patients described in the case series had functional benefits following the use of oral CBD solutions, including significant reductions in social exclusion and anxiety, as well as improved sleep, nutrition, motor coordination, language skills and sensory processing. Two of the patients described had re-emergence of a number of symptoms of SXF after stopping treatment.
Pharmacotherapy is aimed at alleviating the secondary symptoms of the disease, such as self-injury, aggression, depression and anxiety, and includes mainly antidepressants and antipsychotics.
Previous studies have shown that many of the abnormal symptoms of Fragile X syndrome are due to a lack of regulation of the endocannabinoid system and reduced stimulation of their receptors due to a lack of natural endocannabinoids for to bind to it. Studies have shown that CBD consumption increases levels of endocannabinoid anandamide and AG-2, thus reducing or even neutralizing one of the biological mechanisms of abnormal cell function in Fragile X syndrome. "
Although a number of drugs have been developed to target specific systems (GABA agonists), CBD has the potential to produce a multifaceted effect for people with FXS because of its multiple benefits and mechanisms of action.